公司資料
Xeris Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- XERS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
8.52 USD (-0.93%)
收盤價
最後更新: 2026年8月17日
1.04B USD
市值
股價為何變動
As of Aug 17, 2026, XERS closed down 0.93% at $8.52. No new same-company headline was identified in the current news window.
公司概覽
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。